Nagase Satoru, Ohta Tsuyoshi, Takahashi Fumiaki, Yaegashi Nobuo
Department of Obstetrics and Gynecology, Yamagata University, Faculty of Medicine, Yamagata, Japan.
Department of Information Science, Iwate Medical University, Morioka, Japan.
J Obstet Gynaecol Res. 2021 May;47(5):1631-1642. doi: 10.1111/jog.14724. Epub 2021 Feb 25.
To provide information including the trend of gynecological malignancies in Japan, we hereby present the Annual Patient Report for 2017 and the Annual Treatment Report for 2012, on the outcomes of patients who started treatment in 2012.
The Japan Society of Obstetrics and Gynecology maintains an annual tumor registry, where information on gynecological malignancies from various participating institutions is gathered. The data of patients whose treatment with gynecologic malignancies was initiated in 2017 were analyzed retrospectively. Survival of the patients who started treatment with cervical, endometrial and ovarian cancer in 2012 was analyzed by using the Kaplan-Meier, log-rank and Wilcoxon tests.
Treatment was initiated in 2017 for 7710 patients with cervical cancer; 11 120 with endometrial cancer; 7029 with ovarian, tubal and peritoneal cancer; 2164 with ovarian borderline tumors; and with the others (213 vulvar cancer, 139 vaginal cancer, 366 uterine sarcoma, 41 uterine adenosarcoma and 131 trophoblastic diseases). This clinicopathological information was summarized as the patient annual report. The 5-year survival rates of the patients with cervical cancer were 92.9, 75.5, 58.2 and 26.7% for stages I, II, III and IV, respectively. The 5-year survival rates for the patients with endometrial cancer were 93.6, 85.6, 72.6 and 27.3% for stages I, II, III and IV, respectively. The 5-year survival rates for the patients with ovarian cancer (surface epithelial-stromal tumors) were 92.5, 83.5, 49.5 and 30.8% for stages I, II, III and IV, respectively.
The annual tumor report is an important survey that provides knowledge on gynecological malignancy trends in Japan.
为提供包括日本妇科恶性肿瘤趋势在内的信息，我们特此呈现2017年年度患者报告以及2012年年度治疗报告，内容涉及2012年开始接受治疗的患者的治疗结果。
日本妇产科学会维持一个年度肿瘤登记处，收集来自各个参与机构的妇科恶性肿瘤信息。对2017年开始接受妇科恶性肿瘤治疗的患者数据进行回顾性分析。采用Kaplan-Meier法、对数秩检验和Wilcoxon检验分析2012年开始接受宫颈癌、子宫内膜癌和卵巢癌治疗的患者的生存率。
2017年开始接受治疗的患者中，宫颈癌患者7710例；子宫内膜癌患者11120例；卵巢、输卵管和腹膜癌患者7029例；卵巢交界性肿瘤患者2164例；其他患者（213例外阴癌、139例阴道癌、366例子宫肉瘤、41例子宫腺肉瘤和131例滋养细胞疾病）。这些临床病理信息被汇总为患者年度报告。宫颈癌患者I、II、III和IV期的5年生存率分别为92.9%、75.5%、58.2%和26.7%。子宫内膜癌患者I、II、III和IV期的5年生存率分别为93.6%、85.6%、72.6%和27.3%。卵巢癌（表面上皮-间质肿瘤）患者I、II、III和IV期的5年生存率分别为92.5%、83.5%、49.5%和30.8%。
年度肿瘤报告是一项重要的调查，提供了日本妇科恶性肿瘤趋势的相关知识。
